Presentations

Presentations

PRI Presentations

  1. Wilcox, C.S.; Grosz, D.E.; Tong, M.; Rosenberg, D.A.; Morrissey, J.L.; De Francisco, D.F.; Feldman, C.R.; Henry, M.M.; Badgett, L.M. and Oskooilar, N.  “Serving the Needs of Our Increasingly Diverse Population: It All Begins with Recruitment!” ASCP Annual Meeting, Miami Beach, Florida, June 1, 2017.

  2. Wilcox, C.S.; Oskooilar, N.; Tong, M.; Grosz, D.; Henry, M.; Morrissey, J.; Washington, J. and De Francisco, D.  “A Double-Blind, Randomized, Placebo-Controlled, Phase-2, Dose Selection Study of Lorcaserin Hydrochloride for Smoking Cessation: Different Analyses Produce Markedly Different Results,” Society for Research on Nicotine & Tobacco (SRNT) Annual Meeting, Florence, Italy, March 9, 2017.

  3. Wilcox, C.S.; Tong, M.; Oskooilar, N.; Morrissey, J.L.; De Francisco, D.; Henry, M.; Badgett, L. and Grosz, D.  “A 12-Week, Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Phase-2, Dose Selection Study of Lorcaserin Hydrochloride for Smoking Cessation: Preliminary Report,” 55th Annual ACNP Meeting, Hollywood, Florida, December 7, 2016.

  4. Wilcox, C.S.; Oskooilar, N.; Morrissey, J.L.; Rosenberg, D.; Tong, M.; Henry, M.; Badgett, L. and Grosz, D.  “Could a Paradigm Shift in Consumptive Disorders Research Benefit Patients and Sponsors Alike? A Smoking Cessation Case Study Reinforces - The Manner in Which We Look at Things, Determines What We See!” CNS Summit 2016, Boca Raton, Florida, October 28, 2016.

  5. Wilcox, C.S.; Oskooilar, N.; Morrissey, J.L.; De Francisco, D.F.; Guevarra, K.A.; Grosz, D.E.; Henry, M.M.; Litzinger, J.D. and Tong, M.  “Smoking Cessation in Patients with a Prior or Current Psychiatric Disorder: A Double-Blind Comparative Analysis of the Neuropsychiatric Safety and Efficacy of Varenicline, Bupropion, Nicotine Replacement Therapy [NRT] and Placebo” 22ndAnnual Meeting of the Society for Research on Nicotine and Tobacco, Chicago, Illinois, March 3, 2016.

  6. Wilcox, C.S.; Oskooilar, N.; Guevarra, K.A.; Tong, M.; Grosz, D.E.; Morrissey, J.L.; Henry, M.M. and De Francisco, D.F. “A Double-Blind, Active- and Placebo-Controlled Evaluation of the Neuropsychiatric Safety and Efficacy of Varenicline and Bupropion for Smoking Cessation in Subjects with (Pre-Existing) Psychiatric Disorders: An Objective Blinded Analysis” 54th Annual ACNP Meeting, Hollywood, Florida, December 7, 2015.

  7. Wilcox, C.S.; Oskooilar, N.; Morrissey, J.L.; Tong, M.; Grosz, D.E.; Guevarra, K.A.; Feldman, C.R. and  De Francisco, D.F. “The Efficacy of Varenicline Compared to Placebo for Smoking Cessation Using a Reduce-to-Quit Strategy: One Research Center’s Results” 21st Annual SRNT Meeting, Philadelphia, Pennsylvania, February 26, 2015.

  8. Wilcox, C.S.; Oskooilar, N.; Guevarra, K.A.; Tong, M.; Morrissey, J.L.; Grosz, D.E. and  De Francisco, D.F. “Smoking Cessation Through Reduction: Does It Enhance Or Diminish Successful Quitting?” 53rd Annual ACNP Meeting, Phoenix, Arizona, December 9, 2014.

  9. Wilcox, C.S.; Oskooilar, N.; Guevarra, K.A.; Tong, M.; Morrissey, J.L.; Grosz, D.E. and De Francisco, D.F.  “Preliminary Report: Does a ‘Reduce-to-Quit’ Smoking Cessation Strategy Increase or Decrease Success?”  15th Annual Meeting of the Society for Research on Nicotine and Tobacco (SRNT) Europe, Santiago de Compostela – Galicia, Spain, September 20, 2014.

  10. Romano, S.; Jovic, S.; Burch, D. and Wilcox, C.S. “Real Time: CNS Edition – A Candid and Interactive Session,” moderated by Amir Kalali, M.D. – 5th Annual CNS Summit Conference, Boca Raton, Florida, November 15, 2014.

  11. Wilcox, C.S. and Lucariello, V.M.  “Hidden Costs for Sites and Sponsors: What costs are not in study budgets but not ‘the cost of doing business’?” MAGI’s Clinical Research Conference – 2014 East, Philadelphia, Pennsylvania, May 5, 2014.

  12. Wilcox, C.S.; Morrissey, J.L.; Oskooilar, N.; Henry, M.M.; Grosz, D.E.; Tong, M. and De Francisco, D.F. “Protocol Complexity and Enrollment Eligibility Exclusivity: Are Today’s Depression Study Volunteers Truly Representative?” 52nd Annual ACNP Meeting, Hollywood, Florida, December 10, 2013.
     
  13. Wilcox, C.S. – Panelist. “Stakeholder Collaboration at the Site Level: Improving Clinical Trial Success,” CNS Summit Conference, Boca Raton, Florida, November 16, 2013.
     
  14. Shiovitz, T.M.; Wilcox, C.S.; Gevorgyan, L.; Mehra, V. and Mangano, T.C. “Using a Subject Registry to Create a Duplicate-Free Corridor for Conducting Clinical Trials,” CNS Summit Conference, Boca Raton, Florida, November 15, 2013.
     
  15. Shiovitz, T.M.; Manlosa, N.B.; Gevorgyan, L.; Zarrow, M.E. and Wilcox, C.S. “Characteristics of Duplicate Subjects in a Clinical Trial Subject Registry,” 53rd Annual NCDEU Meeting, Hollywood, Florida, May 29, 2013.
     
  16. Wilcox, C.S.; Oskooilar, N.; Morrissey, J.L.; Grosz, D.E.; Litzinger, J.D.; Henry, M.M.; Feldman, C.R. and De Francisco, D.F. “Research Fraud and Failed Clinical Trials via Fictitious Study Participants: Is it an American or an International Problem?” 25th Annual Drug Information Association (DIA) EuroMeeting, Amsterdam, Netherlands, March 3-6, 2013.
     
  17. Wilcox, C.S.; Oskooilar, N.; Morrissey, J.L.; Henry, M.M.; Grosz, D.E. and Tong, M. “The Failed CNS Studies Phenomenon: Is the Final Factor Looking Us Right in the Eye?” 51st Annual ACNP Meeting, Hollywood, Florida, December 5, 2012.
     
  18. Shiovitz, T.M.; Wilcox, C.S.; Gevorgyan, L.; Morrissey, J.L.; Zarrow, M.E. and Shawkat, M.A. “CNS Sites Cooperate to Detect Duplicate Subjects with a Clinical Trial Subject Registry,” 3rd Annual CNS Summit Meeting, Boca Raton, Florida, November 16, 2012.
     
  19. Wilcox, C.S.; Oskooilar, N.; Tong, M.; Morrissey, J.L.; Henry, M.M.; Grosz, D.E. and De Francisco, D.F. “Statistical Analyses in Smoking Cessation Clinical Trials: A Simplified Model Encompassing More Complexity,” 14th Annual Meeting of the Society for Research on Nicotine and Tobacco (SRNT) Europe, Helsinki, Finland, August 31, 2012.
     
  20. Wilcox, C.S.; Oskooilar, N.; Morrissey, J.L.; Grosz, D.E.; Henry, M.M.; Guevarra, K.A. and De Francisco, D.F. “The Impact(s) of Family Psychiatric History on Signal Detection and Placebo-Response: Meta-Analysis,” 52nd Annual NCDEU Meeting, Phoenix, Arizona, May 31, 2012.
     
  21. Wilcox, C.S.; Oskooilar, N.; Tong, M.; Morrissey, J.L.; De Francisco, D.F.; Henry, M.M. and Grosz, D.E. “Do Current Internet-Based Patient Recruitment Methods Impact Patient Retention and Completion Rates in Depression Studies and Are These Metrics Truly Indicative of Positive Outcomes?”  Accepted for Presentation. 50th ACNP Annual Meeting, Waikoloa Beach, Hawaii, December 7, 2011.
     
  22. Wilcox, C.S. “The Costs and Consequences of Study Complexity: Site Perspective,”  Invited Speaker,  CNS Summit Annual Meeting, Boca Raton, Florida, November 18, 2011.
     
  23. Wilcox, C.S.; Oskooilar, N.; Katz, B.B.; Grosz, D.E.; Tong, M.; Morrissey, J.L.; Henry, M.M. and De Francisco, D.F. “A Randomized, Double-Blind, Placebo-Controlled, Pooled Data Single-Site Assessment of the Efficacy and Safety of Vilazodone in Patients with Major Depressive Disorder,” 51st Annual NCDEU Meeting, Boca Raton, Florida, June 15, 2011.
     
  24. Harris-Collazo, R.; Wilcox, C.; Erickson, J., Billes, S.K.; Kim, D. and Dunayevich, E. “An Open-Label Study of Naltrexone SR/Bupropion SR Combination Therapy for Smoking Cessation in Overweight and Obese Subjects,” 11th International Congress on Obesity, Stockholm, Sweden, July 11-15, 2010. 
     
  25. Wilcox, C.S.; Noble, E.P.; Oskooilar, N.; Henry, M.M.; Ritchie, T. L.; Grosz, D.E.; Katz, B.B. and Heiser, J.F. “Biomarkers and Expediting Drug Development: An Interim Report on the Molecular Genetic (DRD2) Basis of Nicotine Addiction and Treatment Response,” 50th Annual NCDEU Meeting, Boca Raton, Florida, June 16, 2010.
     
  26. Wilcox, C.S.; Noble, E.P.; Ritchie, T.; Oskooilar, N.; Katz, B.B.; Grosz, D.E.; Henry, M.M.; Morrissey, J.L. and De Francisco, D.F. “Integrating Pharmacogenomics into Drug Development: A Preliminary Report on a Study of the Molecular Genetic (DRD2) Basis of Nicotine Addiction and Treatment Response in Cigarette Smokers,” 48th Annual American College of Neuropsychopharmacology Meeting, Hollywood, Florida, December 9, 2009.
     
  27. Wilcox, C.S.; Oskooilar, N.; Morrissey, J.L.; Henry, M.M.; Grosz, D.E.; Katz, B.B. and De Francisco, D.F. “Transforming Patient Recruitment and Retention Strategies for CNS Clinical Trials: Today's Patient Perspective on the Transactional Model,” 49th Annual NCDEU Meeting, Hollywood, Florida, July 1, 2009.
     
  28. Dunayevich, E.; Erickson, J.; Oskooilar, N.; Billes, S.J. and Wilcox, C.S.  “Naltrexone SR/Bupropion SR Combination for Smoking Cessation and Prevention of Associated Weight Gain in Overweight and Obese Subjects,” 162nd Annual American Psychiatric Association Meeting, San Francisco, California,  May 20, 2009.
     
  29. Wilcox, C.S.; Oskooilar, N.; Katz, B.B.; Henry, M.M.; Tong, M.; Grosz, D.E.; Morrissey, J.L. and De Francisco, D.F.  “A Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Vilazodone in Patients with Major Depressive Disorder: Results from a Single Center,” 47th Annual American College of Neuropsychopharmacology (ACNP) Meeting, Scottsdale, Arizona, December 10, 2008.
     
  30. Wilcox, C.S.; Oskooilar, N.; Tong, M.; Grosz, D.E.; Morrissey, J.L.; Katz, B.B.; Henry, M.M. and De Francisco, D.F.  “Do Depressed Obese Research Patients Respond Differently to Antidepressant Treatment When Compared with Non-Obese Depressed Patients?”  48th Annual NCDEU Meeting, Phoenix, Arizona, May 29, 2008. 
     
  31. Wilcox, C.S.; Morrissey, J.L.; Grosz, D.E.; Heiser, J.F.; Henry, M.M.; Oskooilar, N.; Katz, B.B. and De Francisco, D.F.  “Are Adult Attention-Deficit Hyperactivity Disorder Research Subjects Representative of the Adult Attention-Deficit Hyperactivity Disorder Population at Large?”  46th Annual American College of Neuropsychopharmacology (ACNP) Meeting, Boca Raton, Florida, December 10, 2007.
     
  32. Wilcox, C.S.; Heiser, J.F.; Katz, B.B.; Oskooilar, N.; Henry, M.M.; Grosz, D.E.; Morrissey, J.L.; Noble, E.P. and De Francisco, D.F.  “A Double-Blind Study Comparing Varenicline with Bupropion-SR and Placebo for Smoking Cessation: Results from a Single Center,”  45th Annual American College of Neuropsychopharmacology (ACNP) Meeting, Hollywood, Florida, December 4, 2006.
     
  33. Wilcox, C.S.; Oskooilar, N.; Katz, B.B.; Grosz, D.E.; Morrissey, J.L.; Henry, M.M. and De Francisco, D.F. “Pharmacogenomics from the Atypical Depression Study Participants’ Perspective,” 46th Annual NCDEU Meeting, Boca Raton, Florida, June 14, 2006.

  34. Wilcox, C.S.; Heiser, J.F.; Katz, B.B.; Thach, A.L.; Henry, M.M.; Cooper, M.E.; Oskooilar, N.; Morrissey, J.L. and Grosz, D.E. “Behavioral, Demographic and Socioeconomic Variables as Potential Predictors of Successful Smoking Cessation, Vis-à-Vis a Clinical Trial,” 11th Annual Society for Research on Nicotine and Tobacco (SRNT) Meeting [and Joint 7th Annual SRNT European Conference], Prague, The Czech Republic, March 21, 2005.

  35. Wilcox, C.S.; Morrissey, J.L.; Hardy, A.I.; Heiser, J.F.; Katz, B.B.; Adkins, D.M.; Tong, M. and Grosz, D.E. “Predictors of Success in Smoking Cessation Studies: An Analysis of Socioeconomic, Behavioral and Demographic Variables,” 43rd Annual American College of Neuropsychopharmacology (ACNP) Meeting, San Juan, Puerto Rico, December 15, 2004.

  36. Wilcox, C.S.; Katz, B.B.; Heiser, J.F.; Hardy, A.I.; Cho, F.E.; Adkins, D.M.; Morrissey, J.L. and Grosz, D.E. “Profiling Smoking Cessation Research Subjects: Demographic and Baseline Characteristics as Predictors of Retention/Completion,” 42nd Annual American College of Neuropsychopharmacology (ACNP) Meeting, San Juan, Puerto Rico, December 9, 2003.

  37. Wilcox, C.S.; Katz, B.B.; Heiser, J.F.; Cho, F.E.; Morrissey, J.L.; Grosz, D.E.; Hardy, A.I.; DeFrancisco, D.F. "Placebo Response and Anxiety Disorders: A Critical Evaluation of Influential Variables," 16th European College of Neuropsychopharmacology (ECNP) Congress, Prague, Czech Republic, September 23, 2003.

  38. Wilcox, C.S.; Morrissey, J.L.; Cho, F.E.; Heiser, J.F.; Katz, B.B.; Grosz, D.E.; Tong, M. and DeFrancisco, D. "Placebo Response and Social Anxiety Disorder: ‘What Happened to Reliable Predictors?’," 43rd Annual NCDEU Meeting, Boca Raton, Florida, May 28, 2003.

  39. Wilcox, C.S.; Morrissey, J.L.; Heiser, J.F.; Cho, F.E.; Grosz, D.E.; Katz, B.B. and DeFrancisco, D.F. "Venlafaxine-ER vs. Placebo in Adults with Generalized Social Anxiety Disorder," 41st Annual American College of Neuropsychopharmacology (ACNP) Meeting, San Juan, Puerto Rico, December 11, 2002.

  40. Wilcox, C.S.; Heiser, J.F.; Rapaport, M.H.; Londborg, P. and Schwartz, G. "Reboxetine Augmentation of Fluoxetine for Patients with Major Depressive Disorder: An 8-Week Open-Label Study," European College of Neuropsychopharmacology (ECNP) Congress, Barcelona, Spain, October 6, 2002.

  41. Wilcox, C.S., Heiser, J.F., Rapaport, M.H., Londborg, P.D. and Schwartz, G.E. "Reboxetine Augmentation of Fluoxetine for Patients with Major Depressive Disorder: An 8-Week Open-Label Study," 42nd Annual NCDEU Meeting, Boca Raton, Florida, June 11, 2002.

  42. Wilcox, C.S.; Heiser, J.F.; Morrissey, J.L.; Grosz, D.E.; Cho, F.E.; Katz, B.B.; Janko, S.E. and Linden, R.D. "Protocol Design and Predictors of Placebo Response in Anxiety Disorders: Generalized Anxiety Disorder vs. Social Anxiety Disorder," 40th Annual American College of Neuropsychopharmacology (ACNP) Meeting, Waikoloa, Hawaii, December 10, 2001. 

  43. Gibertini, M.; Feiger, A.; Heiser, J.; Shrivastava, R.; Weiss, K.; Smith, W. and Sitsen, Ad. "Gepirone Extended Release (ER): New Evidence for Efficacy in the Treatment of Major Depressive Disorder," 40th Annual American College of Neuropsycho-pharmacology (ACNP) Meeting, Waikoloa, Hawaii, December 10, 2001. 

  44. Thase, M.E. and Wilcox, C.S. "The Efficacy of Citalopram in the Treatment of Patients Who Failed Treatment with Fluoxetine or Paroxetine," submitted for the 14th European College of Neuropsychopharmacology [ECNP] Congress, Istanbul, Turkey, October 13-17, 2001. 

  45. Grosz, D.E.; Morrissey, J.L. and Wilcox, C.S. "Almotriptan is Effective for Multiple Migraine Attacks," 10th International Headache Congress, New York, New York, June 30, 2001.

  46. Wilcox, C.S.; Morrissey, J.L.; Cho, F.E.; Grosz, D.E.; Katz, B.B.; Janko, S.E.; Puppione, A.A. and Heiser, J.F. "The Effects of Gender and Methodology on Homogeneity and Outcomes in Clinical Trials: A Look at Social Anxiety Disorder Research Volunteers," 41st Annual NCDEU Meeting, Phoenix, Arizona, May 30, 2001.

  47. Rapaport, M.H.; Londborg, P.; Heiser, J.F.; Wilcox, C.S.; Bartlett, C.L. and Schwartz, G. "Augmentation with Selective NRI Reboxetine Among Partial Responders to SSRI Therapy: Preliminary Report," 41st Annual NCDEU Meeting, Phoenix, Arizona, May 29, 2001. 

  48. Wilcox, C.S.; Morrissey, J.L.; Cho, F.E.; Heiser, J.F.; Katz, B.B.; Janko, S.E.; Grosz, D.E. and De Francisco, D.F. "Profiling Social Anxiety Disorder Research Subjects: An Evaluation of Symptom Severity, Quality of Life and Overall Representativeness," 39th Annual American College of Neuropsychopharmacology (ACNP) Meeting, San Juan, Puerto Rico, December 11, 2000.

  49. Wilcox, C.S. "Alzheimer's Disease Research Update," invited speaker for City of Norwalk Continuing Education Seminar, Norwalk, California, August 17, 2000.

  50. Spierings, E.L.H.; Gomez-Mancilla, B.; Grosz, D.E.; Rowland, C.R.; Whaley, F.S. and Jirgens, K.J. "Oral Almotriptan vs. Oral Sumatriptan in a Double-Blind, Randomized, Parallel-Group Study of Quality of Life and Health Economics in Migraine Patients," 42nd Annual Scientific Meeting of the American Headache Society (AHS), Montreal, Quebec, Canada, June 24, 2000. 

  51. Wilcox, C.S.; Morrissey, J.L.; Heiser, J.F.; Cho, F.E.; Katz, B.B.; Mijares, C.P. and Grosz, D.E. "Major Depressive Disorders and Migraine Headaches: Is Comorbidity a Serious Threat to Homogeneity?" 40th Annual NCDEU Meeting, Boca Raton, Florida, May 31, 2000.

  52. Spierings, E.L.H.; Gomez-Mancilla, B.; Grosz, D.E.; Rowland, C.R.; Whaley, F.S.; Jirgens, K.J.; McShane, M.M. and Klobucar, T.R. "Oral Almotriptan vs. Oral Sumatriptan in a Double-Blind, Randomized, Parallel-Group Study of Quality of Life and Health Economics in Migraine Patients," American Academy of Neurology, AAN Annual Meeting, San Diego, California, May 3, 2000. 

  53. Wilcox, C.S.; Morrissey, J.L.; Heiser, J.F.; Katz, B.B.; Schneider, A.L.; Delaney, J.E. and Grosz, D.E. "Profiling Migraineurs as Research Subjects: Pharmacoeconomic and Quality of Life Measures," 38th Annual American College of Neuropsychopharmacology (ACNP) Meeting, Acapulco, Mexico, December 14, 1999. 

  54. Thase, M.E.; Ferguson, J.M. and Wilcox, C.S. "Efficacy and Safety of Citalopram in Paroxetine Intolerant Patients," Annual Meeting of the American Psychiatric Association Institute on Psychiatric Services, New Orleans, Louisiana, November 1, 1999. 

  55. Stahl, S.M. and Wilcox, C.S. "Placebo-Controlled Comparison of Citalopram and Sertraline in the Treatment of Anxiety Symptoms in Depressed Patients," 39th Annual NCDEU Meeting, Boca Raton, Florida, June 3, 1999. 

  56. Thase, M.E.; Ferguson, J.M. and Wilcox, C.S. "Citalopram Treatment of Paroxetine Intolerant Patients," 39th Annual NCDEU Meeting, Boca Raton, Florida, June 3, 1999.

  57. Wilcox, C.S.; Cho, F.E.; Heiser, J.F.; Morrissey, J.L.; Katz, B.B.; Grosz, D.E. and De Francisco, D.F. "Placebo Response in Depression Studies: Do Previously Reported Predictors Have Any Utility?" 39th Annual NCDEU Meeting, Boca Raton, Florida, June 2, 1999.

  58. Wilcox, C.S.; Morrissey, J.L.; Heiser J.F.; Katz, B.B.; Cho, F.E.; Grosz, D.E.; Linden, R.D. and De Francisco, D.F. "Patients' Motivations as Potential Predictors of Placebo Response: Yesterday and Today," 37th Annual Meeting, American College of Neuropsychopharmacology, Las Croabas, Puerto Rico, December 14, 1998. 

  59. Wilcox, C.S.; Linden, R.D.; D'Amico, M.F.; McQuade, R.; Schneider, A.L.; Morrissey, J.L. and Heiser, J.F. "Nefazodone in the Treatment of Elderly Patients with Depression," XXIst Collegium Internationale Neuro-Psychopharmacologicum Meeting, Glasgow, Scotland, July 13, 1998.

  60. Wilcox, C.S.; Dren, A.T.; Branconnier, R.J. and Hockley, J.R. "Marketing in Clinical Research--Finding Studies and Patients," 34th Annual Drug Information Association Meeting, Boston, Massachusetts, June 8, 1998. 

  61. Wilcox, C.S.; Linden, R.D.; McQuade, R.; Morrissey, J.L.; D'Amico, M.F.; Schneider, A.L. and Heiser, J.F. "Nefazodone Treatment in Elderly Depressed Patients," 151st Annual American Psychiatric Association Meeting, Toronto, Ontario, Canada, June 2, 1998. 

  62. Wilcox, C.S.; Morrissey, J.L.; Heiser, J.F.; Katz, B.B.; Schneider, A.L.; Bacon, P.F. and De Francisco, D. "Protocol Design and Predictors of Placebo Response: Studies with Antidepressants and Anxiolytics," 36th Annual Meeting, American College of Neuropsychopharmacology, Kamuela, Hawaii, December 10, 1997. 

  63. De Francisco, D. "Stranger Anxiety in Traumatic Stress," 5th Annual Meeting of European Conference on Traumatic Stress, Maastricht, The Netherlands, July 1997.

  64. Wilcox, C.S.; Sambunaris, A. and Sachais, B.A. "Strategies for Successful 'Speedy' Collaboration in Clinical Trials," 33rd Annual Drug Information Association [DIA] Meeting, Montréal, Québec, Canada, June 25, 1997. 

  65. Wilcox, C.S. "Alzheimer's Disease: Research Updates and Caregiving Resources," Invited Speaker--CalTech Senior Care (Faculty and Staff), Connection Lecture Series at California Institute of Technology, Pasadena, California, January 22, 1997.

  66. Wilcox, C.S.; Linden, R.D.; D'Amico, M.F.; Schneider, A.L.; Morrissey, J.L. and Heiser, J.F. "The Tolerability of Nefazodone in the Treatment of Adult and Elderly Patients with Mood Disorders," 35th Annual Meeting, American College of Neuropsycho-pharmacology, San Juan, Puerto Rico, December 9, 1996.

  67. Wilcox, C.S.; Morrissey, J.L.; Heiser, J.F.; Dale, J.L.; Katz, B.B. and Schneider, A.L. "Recruitment of Migraineurs for Clinical Trials: Insights on Rapid Patient Enrollment with Retention," IBC's International Conference on Advances in Treatment and Therapeutic Development in Migraine, Boston, Massachusetts, July 25 & 26, 1996. 

  68. Wilcox, C.S.; Heiser, J.F.; Morrissey, J.L.; Katz, B.B.; Linden, R.D. and Schneider, A.L. "A State-of-the-Art Clinical Study Design for Evaluating Potential Treatments of Consumptive Disorders," 32nd Annual Drug Information Association [DIA] Meeting, San Diego, California, June 11, 1996.

  69. Feiger, A.D.; Kiev, A.; Shrivastava, R.K.; Wisselink, P.G. and Wilcox, C.S. "Nefazodone versus Sertraline in Outpatients with Major Depression: Focus on Efficacy, Tolerability and Effects on Sexual Function and Satisfaction," 36th Annual NCDEU Meeting, Boca Raton, Florida, May 30, 1996. 

  70. Feiger, A.D.; Bielski, R.D.; Bremner, J.; Heiser, J.F.; Trivedi, M. and Wilcox, C.S. "Efficacy of Nefazodone in Continuation Treatment of Depression," 36th Annual NCDEU Meeting, Boca Raton, Florida, May 29, 1996.

  71. Wilcox, C.S.; Wesnes, K.A.; Heiser, J.F.; Simpson, P.M.; Katz, B.B.; Bianca, R. and Happy, J.M. "A Double-Blind, Eight-Way Crossover Comparison of Abecarnil, Lorazepam and Placebo, Alone and After a Single Dose of Alcohol, on Psychometric Performance in Healthy Volunteers," 36th Annual NCDEU Meeting, Boca Raton, Florida, May 29, 1996. 

  72. Wilcox, C.S.; Dale, J.L.; Katz, B.B.; Mijares, C.P.; Morgan, D.L.; Morrissey, J.L.; Wassom, N.J. and Heiser, J.F. "An Enhanced Methodology and Study Design for Studies of Smoking Cessation," 20th Annual Associates of Clinical Pharmacology Convention, Nashville, Tennessee, May 11-15, 1996.

  73. Feiger, A.D.; Bielski, R.D.; Bremner, J.; Heiser, J.F.; Trivedi, M. and Wilcox, C.S. "Efficacy of Nefazodone in Continuation Treatment of Depression," 149th Annual American Psychiatric Association Meeting, New York City, New York, May 7, 1996. 

  74. Wilcox, C.S.; Heiser, J.F.; Morrissey, J.L.; Wisselink, P.G. and Herzog, T. "The D2 Dopamine Receptor and Obesity Drug Trials: The Genetic "Reward" Link," IBC's Second Annual International Symposium on Obesity, Washington, D.C., March 4-6, 1996. 

  75. De Francisco, D. "Forensic Implications of Psychoanalytic Observation on Post Traumatic Stress Disorder," Annual Meeting of the American College of Forensic Examiners, 1996.

  76. Wilcox, C.S.; Heiser, J.F.; Morrissey, J.L.; Linden, R.D. and Schneider, A.L. "Identification of the 'Reward Gene' as a Predictor in Studies of Obesity and Smoking Cessation," 34th Annual Meeting, American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 11, 1995. 

  77. Wilcox, C.S.; Katz, B.B.; Morgan, D.L.; Morrissey, J.L. and Schneider, A.L. "Research Patient Recruitment in the 1990's: The Impacts of Managed Care and Increasing Ethnic Diversity," 35th Annual NCDEU Meeting, Orlando, Florida, June 2, 1995.

  78. Wilcox, C.S.; Cohn, J.B.; Ferguson, J.M.; Dale, J.L. and Fabre, L.F. "A Double-Blind Multicenter Trial of a Low Dose Range and High Dose Range of Gepirone-Extended Release Compared to Placebo in the Treatment of Depressed Outpatients," 35th Annual NCDEU Meeting, Orlando, Florida, June 1, 1995.

  79. Wilcox, C.S. "Alzheimer's Research Update: Midway in the 1990's," Co-sponsored by the Los Angeles Alzheimer's Association and the City of Whittier, Whittier, California, May 4, 1995. 

  80. McEntree, W.J.; Coffey, D.J.; Bondareff, W.; Alpert, M.; Raj, A.B.; Rappaport, S.A.; Finkel, S.I.; Rosenthal, M.H.; DuBoff, E.A.; Jenkyn, L.; Friedhoff, A.; Heiser, J.; Weiner, M. and Richter, E.M. "A Double-Blind Comparison of Sertraline and Nortriptyline in the Treatment of Depressed Geriatric Outpatients," The 148th Meeting of the American Psychiatric Association, 1995.

  81. Wilcox, C.S.; Wesnes, K.A.; Wisselink, P.G.; Simpson, P.M.; Morrissey, J.L. and Happy, J.M. "A Double-Blind, Single-Dose, Four-Way Crossover Comparison of the Effects of Abecarnil, Alprazolam and Placebo in the Evaluation of Cognitive Function in Male Volunteers," 33rd Annual Meeting, American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 13, 1994.

  82. Wilcox, C.S.; Heiser, J.F.; Cohn, J.B.; Dale, J.L.; Linden, R.D.; Katz, B.B.; Morrissey, J.L. and De Francisco, D.F. "Placebo Response in G.A.D. Trials: An Analysis of Purported Predictors," 32nd Annual Meeting, American College of Neuropsycho-pharmacology, Honolulu, Hawaii, December 14, 1993.

  83. Linden, R.D.; Wilcox, C.S.; Heiser, J.F.; Cavanaugh, E.; and Wisselink, P.G. "Are S.S.R.I.s Well Tolerated in Somatizing Depressives?" 33rd Annual NCDEU Meeting, Boca Raton, Florida, June 2, 1993. 

  84. Wilcox, C.S. "Drug Development in the 1990s: Bringing New Drugs to Market in the United States," California State University, Los Angeles, CME Guest Speaker, Los Angeles, California, May 5, 1993.

  85. Crowder, J.; Shrivastava, R.K.; Cohn, C.; Davidson, J.; Dunner, D.; Feighner, J.; Kiev, A. and Patrick, R. "Double Blind, Long-Term Safety and Clinical Acceptability Study of Venlafaxine and Imipramine in Outpatients with Major Depression," American College of Neuropsychopharmacology, 31st Annual Meeting, San Juan, Puerto Rico, December 14-18, 1992.

  86. Wilcox, C.S.; Cohn, J.B.; Katz, B.B.; Mijares, C.P.; De Francisco, D.; Heiser, J.F. and Linden, R.D. "A Placebo-Controlled Study of Two Arylpiperazines in Outpatients with Generalized Anxiety Disorder (GAD)," 31st Annual Meeting, American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 15, 1992. 

  87. Heiser, J.F. "A Mathematical Model of Pathology," The Twenty-Eighth Collegium Internationale Neuropsychopharmacologicum Congress, Nice, France, 28 June - July 1992.

  88. Heiser, J.F. "A Mathematical Model of Pathology," 1er Collique International de Psychiatrie Humanitaire, Medecins du Monde, Bucharest, Rumania, 19-23 May 1992.

  89. Wilcox, C.S.; Ryan, P.J.; Cohn, J.B.; Morrissey, J.M.; Linden, R.D. and Heiser, J.F. "A Fixed-Dose Study of Adinazolam-SR Tablets in Generalized Anxiety Disorder: A Preliminary Report," 30th Annual American College of Neuropsychopharmacology Meeting, San Juan, Puerto Rico, December 9-12, 1991. 

  90. Crowder, J.; Derivan, A.; Borison, R.; Carman, J.; Cunningham, L. and Diamond, B. "6-Week Comparison of Venlafaxine, Trazodone, and Placebo in Major Depression," American College of Neuropsychopharmacology 30th Annual Meeting, San Juan, Puerto Rico, December 9-13, 1991.

  91. Wilcox, C.S.; Cohn, J.B.; Linden, R.D.; Heiser, J.F. and Lucas, P.B. "Predictors of Placebo Response: A Retrospective Analysis," 31st Annual NCDEU Meeting, Key Biscayne, Florida, May 30, 1991. 

  92. Cohn, J.B. "Comparative Efficacy of Impramine with Serotonin Re-Uptake Inhibitors," "Advances in the Treatment of Depression," Clinical Symposium held in conjunction with the 144th Annual Meeting of the American Psychiatric Association, May 12, 1991.

  93. Cohn, J.B.; Wilcox, C.S.; Crowder, J.E.; Guarino, J.J. and Ryan, P.J. "A Controlled Study of Mianserin in Moderately to Severely Depressed Outpatients," American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 10, 1990. 

  94. Cohn, J.B. and Wilcox, C.S. "From Delirium to Dementia," 17th Collegium Internationale Neuro-Psychopharmacologicum, Kyoto, Japan, September 14, 1990. 

  95. Wilcox, C.S.; Crowder, J.E.; Ryan, P.J.; Schwartz, R. and Hyde, G.L. "Oral Pentoxifylline (Trental¨) in Diabetic Patients with Intermittent Claudication," XIth International Congress of Pharmacology, Amsterdam, The Netherlands, July 4, 1990.

  96. Lahmeyer, H.; Docherty, J.; Fillingim, J.; Cohn, J.; Kann, J. and Leppik, I. "The Effect of Zolpidem in Outpatients with Chronic Insomnia," The Association of Professional Sleep Societies, 4th Annual Meeting, Minneapolis, Minnesota, June 27-July 1, 1990.

  97. Crowder, J.; Post, G.L.; Houston, J.; Ferguson, J.; Shu, V. and Pierce, M. "Estazolam Treatment of Insomnia with Anxiety," 143rd American Psychiatric Association Annual Meeting, New York, New York, May 16, 1990.

  98. Wilcox, C.S.; Cohn, J.B.; Crowder, J.E. and Ryan, P.J. "Patient Motivation and Placebo Response," Associates of Clinical Pharmacology, Annual Meeting, Montreal, Quebec, Canada, May 9, 1990.

  99. Cohn, J.B.; Wilcox, C.S. and Lerer, B.E. "Development of an Early Detection Battery for Dementia of the Alzheimer's Type," American College of Neuropsychopharmacology, Maui, Hawaii, December 11, 1989.

  100. Cohn, J.B.; Crowder, J.E.; Wilcox, C.S. and Ryan, P.J. "A Placebo- and Imipramine-Controlled Study of Paroxetine," 29th Annual NCDEU Meeting, Key Biscayne, Florida, June 2, 1989. 

  101. Reisenberg, R.; Cohn, J. and Patterson, W. "Etoperidone in the Treatment of Major Depression: A Placebo-Controlled Clinical Trial," 29th Annual NCDEU Meeting, Key Biscayne, Florida, June 1, 1989.

  102. Cohn, J.B. "On the Practicalities of Being an Expert Witness," American College of Forensic Psychiatry, 6th Annual Symposium in Psychiatry and the Law, Palm Springs (Rancho Mirage), California, March 9-12, 1988. 

  103. Wilcox, C.S.; Cohn, J.B. and Pyke, R.E. "A Six-Week, Double-Blind Comparison of Adinazolam Mesylate and Placebo in Depressed Outpatients," Xth International Congress of Pharmacology, Sydney, Australia, August 27, 1987. 

  104. Wilcox, C.S.; Hamilton, M.; Cohn, J.B. and Addis, B. "The Hamilton Anxiety Rating Scale: A Training Film for the Assessment of Anxious Patients," University of California at Los Angeles, Behavioral Sciences Media Laboratory, April 15, 1987.

  105. Wilcox, C.S.; Hamilton, M.; Cohn, J.B. and Addis, B. "The Hamilton Depression Rating Scale: A Training Film for the Assessment of Depressed Patients," University of California at Los Angeles, Behavioral Sciences Media Laboratory, April 14, 1987.

  106. Cohn, J.B. "Differential Diagnosis of Dementia," Included on Audio-Digest Program, Audio-Digest Foundation of the California Medical Association, March 12, 1987.

  107. Crowder, J. "Acquired Immune Deficiency Syndrome and Sexually Transmitted Diseases: Implications for Medical Education," Consortium of the California Area Health Education Statewide Project and the State of California Department of Health Services, Los Angeles, California, February 11, 1987.

  108. Cohn, J.B. and Wilcox, C.S. "Evaluation of Alzheimer's Disease Diagnostic Criteria," Collegium Internationale Neuro-Psychopharmacologicum, 15th CINP Congress, Puerto Rico, December 16- 20, 1986. 

  109. Cohn, J.B. "Differential Diagnosis of Dementia," University of Kansas, School of Medicine, Geriatric Psychiatry Meeting, Wichita, Kansas, March 21, 1986. 

  110. Cohn, J.B.; Feigenbaum, A.S. and Wilcox, C.S. "Treatment of Alzheimer's Disease with Oral Analogue of ACTH," IV World Congress of Psychiatry, Philadelphia, Pennsylvania, September 9, 1985. 

  111. Cohn, J.B.; Feigenbaum, A.S. and Wilcox, C.S. "An Investigation of ORG 2766 in Primary Degenerative Dementia," II International Congress on Psychogeriatric Medicine, Umeá, Sweden, August 30, 1985. 

  112. Crowder, J. "The Impaired Physician: Monitoring Recovery," American Psychiatric Association Annual Meeting, Dallas, Texas, May 24, 1985.

  113. MacMurray, J.P.; Schultz, M.D.; Berman, J.D.; Aloia, R.C.; Bozzetti, L.P. and Crowder, J. "Prostaglandins and Recovery from Alcoholism," American Psychiatric Association Annual Meeting, Dallas, Texas, May 23, 1985. 

  114. Cohn, J.B. and Wilcox, C.S. "Comparison of Fluoxetine, Imipramine and Placebo in Patients with Major Depressive Disorder," Collegium Internationale Neuro-Psychopharmacologicum 14th CINP Congress, Florence, Italy, July 19-23, 1984.

  115. Cohn, J.B.; Bowden, C. and Rodos, J. "Controlled Evaluation of a New Class of Anti-Anxiety Agents," 78th Annual Scientific Assembly: Southern Medical Association, New Orleans, Louisiana, November 4-6, 1984.

  116. Cohn, J.B. and Wilcox, C.S. "Praxilene in the Treatment of Senile Dementia," International Symposium on Conservative Therapy of Arterial Occlusive Disease, Bonn, Germany, May 25, 1984.

  117. Cohn, J.B.; Feighner, J.P. and Pyke, R.E. "Double-Blind Placebo-Controlled Studies of Adinazolam in Outpatients with DSM-III Major Depressive Episode," 24th Annual NCDEU Meeting, Key Biscayne, Florida, May 23, 1984. 

  118. MacMurray, J.P.; Plummer, O.E. and Crowder, J. "Diagnosis of Alcoholism Using Laboratory Tests," American Psychiatric Association Annual Meeting, Los Angeles, California, May 10, 1984. 

  119. Crowder, J. "Impaired Physicians: Are We Our Brother's Keeper?," American Psychiatric Association Annual Meeting. Los Angeles, California, May 9, 1984. 

  120. Cohn, J.B. and Varga, L. "A Comparison of Nomifensine Maleate, Impramine and Placebo in Geriatric Patients Exhibiting Primary Depression," 137th Annual Meeting of the American Psychiatric Association, Los Angeles, California, May 7-10, 1984. 

  121. Cohn, J.B. and Varga, L. "A Comparison of Nomifensine Maleate, Imipramine and Placebo in Geriatric Patients Exhibiting Primary Depression," American College of Physicians, 65th Annual Meeting, April 26-29, 1984, Atlanta, Georgia.

  122. Wenger, T.L.; Cohn, J.B. and Lyford, A. "Comparison of Electrocardiographic Effects of Bupropion and Amitriptyline," III World Congress of Psychiatry, Vienna, Austria, July 11-16, 1983.

  123. Cohn, J.B.; Stark, P. and Lyford, A. "Fluoxetine Hydrochloride in Treatment of Major Depressive Disorder," III World Congress of Psychiatry, Vienna, Austria, July 11-16, 1983. 

  124. Cohn, J.B. and Wilcox, C.S. "Effect of Withdrawing Treatment After Long-Term Administration of Alprazolam, Lorazepam, or Placebo in Patients with Anxiety Disorder," American College of Neuropsychopharmacology, 21st Annual Meeting, San Juan, Puerto Rico, December 15-17, 1982. 

  125. Cohn, J.B. "Long- and Short-Acting Benzodiazepines," A Beecham Symposium:"A Multidisciplinary Review of the Future Role of the Benzodiazepines" Harrow Weald, Middlesex, England, November 17-19, 1982. 

  126. Cohn, J.B."Double-Blind Safety and Efficacy Comparison of Alprazolam and Placebo in Treatment of Anxiety in Geriatric Patients," Clinical Neuropsychopharmacology Congress, Jerusalem, Israel, July 1982. 

  127. Wenger, T.L.; Cohn, J.B. and Bustrack, J.A. "Comparison of Effects of Bupropion and Amitriptyline on Cardiac Conduction in Depressed Patients" Duke University Medical Center, Psychiatry Update 1982: "An Approach to Dilemmas in the Pharmacotherapy of Depression: A New Generation of Anti-Depressants," Lake Buena Vista, Florida, February 4-5, 1982.

  128. Klett, C.J.; Cohn, J.B. and Gottschalk, L.A. "Advanced State of the Art Testing of New Pharmacologic Agents in Senile Dementia," Annual Meeting, American College of Neuropsychopharmacology, San Diego, California, December 16-18, 1981. 
     
  129. Stern, W.; Rogers, J.; Sato, T.; Miller, L.; Schroeder, D.; Smith, P. and Cohn, J. "Therapeutic Plasma Levels of Antidepressant Bupropion (Wellbutrin)," 12th Clinical Neuropsychopharmacology Congress, Goteborg, Sweden, June 21-26, 1980.